MarÃ-a AsunciÃ³n Esteve-Pastor

List of Publications by Year
in descending order

60 papers	1,087 citations	430754 18 h-index	434063 31 g-index
62 all docs	62 docs citations	62 times ranked	1588 citing authors

#	Article	IF	Citations
1	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace, 2018, 20, 1577-1583.	0.7	93
2	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis and Haemostasis, 2017, 117, 1448-1454.	1.8	74
3	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thrombosis and Haemostasis, 2019, 119, 1901-1919.	1.8	57
4	Long-term bleeding risk prediction in â€˜real worldâ€™ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. Thrombosis and Haemostasis, 2017, 117, 1848-1858.	1.8	56
5	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thrombosis and Haemostasis, 2017, 117, 2261-2266.	1.8	51
6	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke, 2019, 50, 1372-1379.	1.0	48
7	Longâ€Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABCâ€Stroke and CHA ₂ DS ₂ â€VASc Scores. Journal of the American Heart Association, 2017, 6, .	1.6	42
8	Quality of oral anticoagulation with vitamin K antagonists in â€˜real-worldâ€™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace, 2018, 20, 1435-1441.	0.7	39
9	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2020, 73, 749-757.	0.4	38
10	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the â€œReal-Worldâ€•vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.	1.4	28
11	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety, 2017, 16, 1051-1062.	1.0	24
12	Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HASâ€BLED and GARFIELDâ€AF Bleeding Scores. Journal of the American Heart Association, 2018, 7, e009766.	1.6	23
13	Enhancing the â€˜real worldâ€™ prediction of cardiovascular events and major bleeding with the CHA₂DS₂-VASc and HAS-BLED scores using multiple biomarkers. Annals of Medicine, 2018, 50, 26-34.	1.5	22
14	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. Circulation Journal, 2016, 80, 2102-2108.	0.7	21
15	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics, 2018, 40, 114-122.	1.1	21
16	Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 57-65.	1.0	21
17	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2176-2181.	0.7	19
18	Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. European Journal of Internal Medicine, 2019, 61, 48-53.	1.0	19

#	Article	IF	Citations
19	Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry. Journal of the American Heart Association, 2020, 9, e013789.	1.6	19
20	The SAMe-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.	0.6	18
21	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in â€˜real-worldâ€™ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.	0.8	18
22	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. Thrombosis and Haemostasis, 2018, 118, 279-287.	1.8	17
23	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.	1.6	16
24	Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroftâ€“Gault, Modification of Diet in Renal Diseaseâ€4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, .	1.6	16
25	Relationship between multimorbidity and outcomes in atrial fibrillation. Experimental Gerontology, 2021, 153, 111482.	1.2	16
26	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. Journal of General Internal Medicine, 2018, 33, 847-854.	1.3	14
27	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. American Journal of Hypertension, 2017, 30, 1063-1065.	1.0	13
28	A nurseâ€led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. International Journal of Clinical Practice, 2020, 74, e13634.	0.8	13
29	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated â€œReal-Worldâ€•in Patients With Atrial Fibrillation. American Journal of Cardiology, 2018, 122, 785-792.	0.7	12
30	Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. Oncotarget, 2017, 8, 80182-80191.	0.8	12
31	Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. European Journal of Cardiovascular Nursing, 2017, 16, 696-703.	0.4	10
32	Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices. European Journal of Internal Medicine, 2018, 52, 54-59.	1.0	8
33	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA 2 DS 2 -VASc and HAS-BLED. American Heart Journal, 2018, 197, 27-34.	1.2	8
34	Oneâ€year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry. British Journal of Clinical Pharmacology, 2020, 86, 1052-1061.	1.1	7
35	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIIA Registry. Annals of Medicine, 2020, 52, 300-309.	1.5	7
36	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	1.8	7

#	Article	IF	Citations
37	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	1.7	5
38	Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from <scp>FANTASIIA</scp> Registry. European Journal of Clinical Investigation, 2018, 48, e12910.	1.7	5
39	Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?. Thrombosis and Haemostasis, 2019, 119, 1891-1893.	1.8	5
40	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. International Journal of Clinical Practice, 2018, 72, e13069.	0.8	4
41	Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines. PLoS ONE, 2018, 13, e0208069.	1.1	4
42	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	0.7	4
43	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Thrombosis and Haemostasis, 2021, 121, 1107-1114.	1.8	4
44	Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. Cardiology Journal, 2018, 25, 151-154.	0.5	4
45	Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry. Frontiers in Cardiovascular Medicine, 2022, 9, 856222.	1.1	4
46	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open, 2019, 9, e033712.	0.8	3
47	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opinion on Pharmacotherapy, 2020, 21, 1867-1881.	0.9	3
48	Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study. European Journal of Internal Medicine, 2020, 78, 63-68.	1.0	3
49	Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. European Journal of Clinical Investigation, 2021, 51, e13431.	1.7	3
50	Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes. European Journal of Clinical Investigation, 2021, 51, e13505.	1.7	3
51	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. Molecules, 2016, 21, 284.	1.7	2
52	Differences of Matrix Metalloproteinase 2 Expression between Left and Right Ventricles in Response to Nandrolone Decanoate and/or Swimming Training in Mice. Chinese Medical Journal, 2018, 131, 207-212.	0.9	2
53	Chronic Kidney Disease and Thirdâ€Generation P2Y₁₂ Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. Journal of Clinical Pharmacology, 2019, 59, 295-302.	1.0	2
54	Comparison of Aortic Gradient and Ventricular Mass after Valve Replacement for Aortic Stenosis with Rapid Deployment, Sutureless, and Conventional Bioprostheses. Cardiology, 2021, 146, 656-666.	0.6	2

#	Article	IF	Citations
55	Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a â€œReal-worldâ€•Nationwide Registry: Insights From the FANTASIIA Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 316-323.	1.0	1
56	The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. Thrombosis and Haemostasis, 2015, 114, 872-874.	1.8	0
57	EvaluaciÃ³n de los esquemas de riesgo hemorrÃ¡gico HAS-BLED y ORBIT en pacientes con fibrilaciÃ³n auricular no valvular tratados con anticoagulaciÃ³n oral. Revista Espanola De Cardiologia, 2017, 70, 132-133.	0.6	0
58	Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. Revista Espanola De Cardiologia (English Ed), 2017, 70, 132-133.	0.4	0
59	Riesgo embÃ³lico, riesgo isquÃ©mico y riesgo hemorrÃ¡gico. Revista Espanola De Cardiologia Suplementos, 2019, 18, 3-8.	0.2	0
60	Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors. Diabetes Research and Clinical Practice, 2022, 184, 109215.	1.1	0